As a first class contract development and manufacturing organization (CDMO), Rottendorf Pharma has been manufacturing, packaging, and developing formulations and analytical methods for solid oral dosage forms for the global pharmaceutical industry for over 90 years. Our company produces multiple originator and generic drug products annually for big, small, virtual, and global pharmaceutical and biotechnology companies.
Rottendorf Pharma operates by the philosophies of TOTAL PROCESS OWNERSHIP (TPO) and TOTAL TECHNOLOGICAL MASTERING (TTM), in which we work as an extension of our client's organization. We leverage our expertise in optimizing solid dosage form production for our customer's benefit. TPO and TTM reduce our clients' management resource requirements and costs while improving the supply chain and product quality. As our business strategy, Rottendorf Pharma does not have its own product brands in the market and does not hold any product licenses. As a result, we are never in competition with our clients.
Rottendorf Pharma invests in state-of-the-art facilities, featuring best-in-class equipment and technologies, and is staffed with over 1,200 experienced, skilled workers, including many formulation scientists. In our German facilities, compliant with GMP, FDA, ANVISA, and others, the originator and generic drug products are manufactured, packaged, and developed. Clients choose Rottendorf Pharma for our broad range of expertise, global regulatory capabilities, commitment to quality, state-of-the-art facilities, and exceptional customer service. Rottendorf Pharma was recognized with five CMO Leadership Awards in 2015 for excellence in regulatory capabilities, quality, innovation and productivity.